香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 2025年第二次臨時股東大會通告 茲通告 康 希 諾 生 物 股 份 公 司（「本公司」）謹 訂 於2025年11月27日（星 期 四）下 午 二 時 正假座中國天津市河東區衛國道126號天津東凱悅酒店二層悅賓廳1舉 行2025年 第 二 次 臨 時 股 東 大 會（「臨時股東大會」）以 處 理 下 列 事 宜： 特別決議 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 1. 建議取消監事會及修訂公司章程及議事規則，包括： 1.01 建議修訂公司章程； 1.02 建議修訂股東會議事規則；及 1.03 建議修訂董事會議事規則。 普通決議 2. 建議修訂企業管治規則，包括： 2.01 建 議 修 訂《募 集 資 金 管 理 制 度》； 2.02 建 議 修 訂《關 聯 交 易 管 理 制 度》； 2.03 建 議 修 訂《 ...

2025 年第二次临时股东大会会议资料 2025 年 11 月 康希诺生物股份公司 2025 年第二次临时股东大会 证券代码：688185 证券简称：康希诺 康希诺生物股份公司 | 年第二次临时股东大会会议议案 6 2025 | | --- | | 议案一：关于取消监事会、修订《公司章程》及其附件并办理工商变更登记的议案 6 | | 议案二：关于修订部分公司治理制度的议案 7 | | 议案三：关于使用公积金弥补亏损的议案 8 | | 议案四：关于选举第三届董事会独立非执行董事的议案 10 | 康希诺生物股份公司 2025 年第二次临时股东大会 康希诺生物股份公司 2025 年第二次临时股东大会会议须知 为维护全体股东的合法权益，确保股东大会会议秩序和议事效率，保证股东 大会的顺利召开，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、中国证监会《上市公 司股东会规则》以及《康希诺生物股份公司章程》（以下简称"《公司章程》"） 和《康希诺生物股份公司股东大会议事规则》等有关规定，特制定康希诺生物股 份公司（以下简称"公司"）2025 年第二次临时股东大 ...

Group 1 - The company will hold its second extraordinary general meeting of shareholders on November 27, 2025 [2] - A temporary proposal has been added to the agenda, suggesting the use of capital reserves to cover losses [3][19] - The proposal was submitted by Dr. Xuefeng Yu, who holds 7.26% of the company's shares [2][3] Group 2 - The meeting will take place at the Tianjin East Hyatt Hotel, starting at 14:00 [5] - Shareholders can vote online through the Shanghai Stock Exchange's voting system on the day of the meeting [7] - The original date for the equity registration remains unchanged [8] Group 3 - The company reported a cumulative undistributed profit of -1,450,342,128.90 yuan as of December 31, 2024 [17] - The plan involves using 118,388,703.29 yuan from surplus reserves and 1,331,953,425.61 yuan from capital reserves to offset losses [18] - After the implementation of this plan, the company's surplus reserves will be reduced to 0 yuan, and capital reserves will decrease to 5,244,776,299.42 yuan [19] Group 4 - The proposal to use capital reserves to cover losses has been approved by the company's board and supervisory board [20] - The company aims to enhance investor returns and promote high-quality development through this measure [19] - The proposal requires approval from the shareholders' meeting, indicating a level of uncertainty [21] Group 5 - The company will hold a quarterly performance briefing on November 17, 2025, to discuss the third quarter results [23][25] - Investors can submit questions in advance through the Shanghai Stock Exchange's website or via email [24][27] - The meeting will be conducted in an interactive online format [29]

关于 2025 年第二次临时股东大会增加临时提案 的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、股东大会有关情况 证券代码：688185 证券简称：康希诺 公告编号：2025-039 康希诺生物股份公司 1. 股东大会的类型和届次： 2025 年第二次临时股东大会 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | A 股 | 688185 | 康希诺 | 2025/11/21 | 二、增加临时提案的情况说明 公司已于 2025 年 10 月 28 日公告了股东大会召开通知，单独持有 7.26%股 份的股东 XUEFENG YU（宇学峰）博士，在 2025 年 11 月 6 日提出临时提案并 书面提交股东大会召集人。股东大会召集人按照《上海证券交易所科创板上市公 司自律监管指引第 1 号—规范运作》有关规定，现予以公告。 3. 临时提案的具体内容 2. 股东大会召开日期：2025 年 11 月 27 日 3. 股东大会股权登记日： 1. 提案人： ...

Group 1 - The company, Hongyuan Green Energy, announced the completion of the initial grant registration for its 2025 restricted stock incentive plan on November 6, 2025, at the Shanghai branch of China Securities Depository and Clearing Corporation [2]

Core Viewpoint - The Ministry of Industry and Information Technology (MIIT) has announced the list of selected units for the high-performance bioreactor innovation task, aiming to enhance the supply capacity of key equipment for biological manufacturing [2][3]. Summary by Relevant Sections Task Objectives - The initiative focuses on three categories: reactor systems, key components and consumables, and industrial operating systems, with a total of nine tasks aimed at selecting and nurturing units with strong innovation capabilities and mastery of core technologies [2]. Selected Units - Notable units included in the list are: - Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences - Guangzhou Aibaitai Biotechnology - Shanghai Dongfulong - Jiangsu Weiji Wisdom - Shanghai Shunyu Hengping - Shanghai Ailite [5][6]. Task Directions - The tasks cover various directions such as: 1. Microbial parallel bioreactors 2. Cell parallel bioreactors 3. Large cell bioreactors 4. Core physicochemical parameter in-situ monitoring 5. Biological reactor intelligent industrial operating systems [5][6]. Innovation Goals - The goal is to break through several landmark technologies, cultivate typical application scenarios, and accelerate the landing and application of new technologies and products, thereby enhancing the integrated development capability of high-performance bioreactors [2].

Core Viewpoint - The company plans to use its reserves to offset accumulated losses by the end of 2024, aiming to enhance investor returns and support high-quality development [1][2]. Group 1: Financial Situation - As of December 31, 2024, the company's accumulated losses amount to RMB 1.45 billion, with surplus reserves of RMB 118 million and capital reserves of RMB 6.5767 billion [1]. - The accumulated losses are primarily due to past operational results, and the proposed capital reserve offset will come entirely from shareholder contributions in the form of share premiums [1]. Group 2: Proposed Plan - The company suggests using RMB 118 million from surplus reserves and RMB 1.332 billion from capital reserves to fully offset the accumulated losses, totaling RMB 1.45 billion [1]. - After the completion of the loss offset plan, surplus reserves will be reduced to RMB 0, capital reserves will decrease to RMB 5.245 billion, and accumulated losses will be fully eliminated [2].

Core Viewpoint - The company plans to use its reserves to offset accumulated losses as of December 31, 2024, amounting to RMB 1.45 billion [1] Financial Summary - The company's accumulated losses amount to RMB 1.45 billion, with surplus reserves of RMB 118 million and capital reserves of RMB 6.577 billion [1] - The proposal includes using RMB 118 million from surplus reserves and RMB 1.332 billion from capital reserves to cover the losses [1] - After the proposed plan, surplus reserves will be reduced to RMB 0, capital reserves will decrease to RMB 5.245 billion, and accumulated losses will be fully offset to RMB 0 [1]

Core Viewpoint - The company plans to use its reserves to offset accumulated losses by December 31, 2024, in order to enhance investor returns and support high-quality development [1][2] Financial Summary - As of December 31, 2024, the company's accumulated losses amount to RMB 1.45 billion, with surplus reserves of RMB 118 million and capital reserves of RMB 6.5767 billion [1] - The proposal includes using RMB 118 million from surplus reserves and RMB 1.332 billion from capital reserves to cover the total accumulated losses of RMB 1.45 billion [1] - After the loss offset plan is completed, surplus reserves will be reduced to RMB 0, capital reserves will decrease to RMB 5.245 billion, and accumulated losses will be fully offset to RMB 0 [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 香港，2025年11月7日 於 本 公 告 日 期，本 公 司 董 事 會 包 括 執 行 董 事Xuefeng YU博 士、Shou Bai CHAO博 士及王靖女士；非執行董事李志成先生；以及獨立非執行董事桂水發先生、劉建 忠先生及張耀樑先生。 （股份代號：6185） 证券代码：688185 证券简称：康希诺 公告编号： 2025-039 海外監管公告 本 公 告 乃 康 希 諾 生 物 股 份 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市規則第13.10B條而發表。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 發 的《康 希 諾 生 物 股 份 公 司 關 於2025年 第 二 次 臨 時 股 東 大 會 增 加 臨 時 提 ...